Apollo Hospitals' Restructuring Plan Wins NCLT Approval

NCLT Chennai Approves Restructuring Scheme

The National Company Law Tribunal (NCLT) in Chennai has officially approved Apollo Hospitals Enterprise Ltd's composite scheme of arrangement. The company received the certified order on April 9, 2026, following the pronouncement on March 26, 2026. This crucial step clears the path for the company's planned business restructuring.

The scheme involves subsidiaries Apollo Healthco Limited, Keimed Private Limited, and Apollo Healthtech Limited.

Boosting Focus and Efficiency

The primary goal of this restructuring is to establish distinct, focused entities for Apollo Hospitals' pharmacy distribution and digital health businesses. This separation is intended to allow for more tailored management strategies and better capitalize on market opportunities. The company anticipates enhanced operational efficiency and unlocking shareholder value by streamlining operations in these high-growth segments.

Background on the Restructuring

Apollo Hospitals Enterprise Ltd is a leading integrated healthcare provider in India, known for its extensive network of hospitals, pharmacies, and digital health services. It operates India's largest for-profit private hospital network.

This initiative builds on earlier integrations, such as the formation of Apollo HealthCo in 2021, which merged Apollo Pharmacy with the digital platform Apollo 24/7. Keimed, a significant distribution arm, is also integral to the plan, handling wholesale and retail pharmaceutical distribution.

A composite scheme of arrangement, a legal process governed by Sections 230-232 of the Companies Act, 2013, allows for complex corporate restructurings like mergers and demergers. The Competition Commission of India (CCI) had previously approved this multi-layered plan.

Key Changes Under the Scheme

The approved scheme will facilitate the creation of independent companies dedicated to pharmacy distribution and digital health. This is expected to foster more agile operations and improve synergies between offline pharmacies, distribution networks, and online health platforms.

Implementation and Next Steps

While the NCLT approval is a major milestone, the scheme requires final consent from specific shareholder and creditor groups. Formal meetings for shareholders and creditors are scheduled for May 16-17, 2026. Further regulatory and stock exchange approvals are necessary for the full implementation of the restructuring.

Implementation Risks

The successful execution of the restructuring hinges on securing the necessary approvals from shareholders and creditors at the upcoming meetings. No specific risks were highlighted in the filing beyond this approval process.

Competitive Landscape

In India's rapidly expanding e-pharmacy and digital health market, Apollo's newly structured entities will face competition from established players like Reliance Retail's Netmeds, Tata 1mg, and PharmEasy.

Shareholder and Creditor Details

The scheme involves approximately 1,78,239 equity shareholders and 6,418 unsecured creditors of the demerged company.

What to Track Next

Investors and stakeholders will be monitoring several key developments:

• The outcomes of the shareholder and creditor meetings scheduled for May 16-17, 2026.
• The submission of the NCLT order to the Registrar of Companies.
• Securing final approvals from the BSE and NSE for the listing of the resultant entity.
• The official date when the restructuring scheme becomes legally effective.
• The future performance and growth trajectory of the newly structured pharmacy and digital health businesses. The company has a stated aim to achieve Rs 25,000 crore revenue for this segment by FY27.